iShares US Pharmaceuticals ETF
87 hedge funds and large institutions have $111M invested in iShares US Pharmaceuticals ETF in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 37 reducing their positions, and 15 closing their positions.
21.29% more ownership
Funds ownership: 81.21% → 102.5% (+21%)
7% more capital invested
Capital invested by funds: $104M → $111M (+$7.14M)
4% less funds holding
Funds holding: 91 → 87 (-4)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
59% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$22.2M |
| 2 |
Jane Street
New York
|
+$4.83M |
| 3 |
SCP
Syntal Capital Partners
Midland,
Texas
|
+$2.63M |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
+$804K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$589K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.29M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.93M |
| 3 |
KCM
Karp Capital Management
Sausalito,
California
|
-$2.93M |
| 4 |
AWA
ARS Wealth Advisors
St. Petersburg,
Florida
|
-$2.5M |
| 5 |
Morgan Stanley
New York
|
-$1.32M |
IHE Hedge Fund Activity: Q2 2019 in Review
87 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2019, worth a combined $111M — up 6.9% from $104M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of IHE and 11 opened new positions — a net loss of 4 holders — while 37 trimmed existing stakes and 15 added.
The largest buyer was Goldman Sachs, adding an estimated $22.2M. The largest seller was Citadel Advisors, cutting an estimated $4.29M.
- 87 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2019, down from 91 in Q1 2019.
- Funds reported $111M of iShares US Pharmaceuticals ETF stock for Q2 2019, up 6.9% quarter-over-quarter.
- 11 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2019 and 15 closed out, a net change of -4 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2019 was Goldman Sachs, an estimated $22.2M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2019 was Citadel Advisors, an estimated $4.29M sold.
Based on aggregated 13F filings for Q2 2019.